Objective To investigate the efficacy of rituximab combined with bendamustine in the treatment of advanced mantle cell lymphoma.Methods A total of 82 patients with advanced mantle cell lymphoma admitted to Xinyang Central Hospital from October 2020 to October 2022 were divided into observation group and conventional group according to the random number table method,with 41 cases in each group.The conventional group received phenelztuximab treatment,and the observation group received phenelztuximab combined with bendamustine.The two groups of patients with Kahn's score,clinical efficacy,serum vascular endothelial growth factor(VEGF)levels and adverse drug reactions were compared.Results The Kahn's score of the observation group after 4 weeks of treatment was higher than that of the conventional group,and the level of VEGF was lower than that of the conventional group(P＜0.05).The objective remission rate of the observation group was higher than that of the conventional group,and the incidence of adverse reactions was lower than that of the conventional group(P＜0.05).Conclusion Rituximab combined with bendamustine in the treatment of advanced mantle cell lymphoma can improve clinical symptoms with definite efficacy,and can reduce the level of serum VEGF and the incidence of adverse reactions in patients,which is worthy of promotion and application.
维普
万方数据